Cancer Prevention & Research Institute of Texas Cancer Prevention & Research Institute of Texas

Annual Report

Visit CPRIT's Homepage   |   2022 Annual Report   >  FY 2022 Highlights
Copy the URL below to share anywhere

FY 2022 Highlights

Building on the momentum launched by Texas voters 15 years ago and reauthorized by a decisive statewide vote in November 2019, CPRIT and its grantees advanced innovative research and prevention efforts throughout the state. The year 2022 saw numerous milestones and significant accomplishments for CPRIT and our grantees and grantee institutions, but as always, the beginning and end of our work at CPRIT rests in our grant awards.


CPRIT surpassed $2 Billion in Academic Research grants

As of the end of Fiscal Year 2022, CPRIT had awarded more than $2 billion in academic research grants to almost three dozen research institutions and organizations across Texas. As a result of CPRIT’s investment in active cancer research, Texas institutions have raised over $2.5 billion in additional funding.


CPRIT funded more than 8 million prevention services statewide

This year, the CPRIT prevention program reached a new milestone, surpassing 8 million prevention services provided to Texans in all 254 counties. CPRIT has awarded 274 grants totaling $327 million to institutions and community-based prevention programs across the state.


CPRIT invested in more than 50 Texas companies for product development

Since its inception, a crucial part of the CPRIT mission has been to provide early-stage investments in Texas companies developing new cancer-fighting drugs and therapies. CPRIT awarded a Product Development grant to its 50th company in 2022.


Notable Firsts

  • Perimeter Medical Imaging AI, Inc. announced the first commercial installation of its flagship Perimeter S-Series OCT system at a North Texas hospital on December 20, 2021. In August, Perimeter announced the first commercial placement of the same system in the state of California. Perimeter, based in Dallas, received a $7.4 million CPRIT Product Development Research award in 2019 (DP190087) to develop an optical tissue imaging system for breast conserving surgery.

  • Highlighting the global reach of CPRIT, Vanderlei Bagnato, Ph.D., was approved for a nearly $6 million recruitment grant (RR20054) to come to the Texas A&M Engineering Experiment Station from the University of Sao Paulo, Brazil – the first scholar recruited from South America. Dr. Bagnato is a member of the National Academy of Sciences in the United States, an extraordinary accomplishment for an international scientist.

  • The National Cancer Institute (NCI) selected Texas Southern University as a designated laboratory to provide contract services for cancer drug discovery and development in the U.S. through the NCI Therapeutics (NExT) program. Texas Southern University is the only institution selected from Texas and the only HBCU participating in the NexT program among a group of elite institutions. CPRIT awarded Texas Southern University a $5.1 million Academic Research grant (RP180748) in 2018 to fund the state-of-the-art drug development core facility, which provides pre-clinical drug development resources to facilitate rapid advancement of novel cancer drug candidates to clinical trials.

  • The University of Houston Downtown received its first CPRIT award. The $1 million prevention grant (PP220036) will fund a program to increase the use of life-saving HPV vaccination services among medically underserved young adults in seven Texas counties. UHD is in the heart of downtown Houston with a diverse student population.

Fiscal Year 2022 Grant Awards

CPRIT strives to generate the greatest possible benefit for Texans when awarding grants. The agency supports academic research, product development, and prevention projects that show great scientific promise, meet critical needs, and advance the state’s life science ecosystem. CPRIT’s investments help grantees build novel facilities, achieve scientific breakthroughs, reach clinical milestones, and detect cancers and cancer precursors earlier.

Over the last 13 years, CPRIT has invested $3.12 billion in Texas’ universities, enterprises, and organizations. CPRIT supports the cancer continuum from discovery to delivery, awarding more than 1,794 grants to academic research, product development, and prevention projects across Texas through August 31, 2022.

$266 million in Grant Funds Awarded and 117 Grants Approved in FY 2022

63.02 %

$167.9 million for Academic Research in 90 Academic Research and Recruitment Awards

26.6 %

$70.87 million for Product Development Research in 11 awards

10.37 %

$27.63 million for Prevention in 16 Awards

33 Organizations Receiving Grants

  • Ares Immunotherapy, Inc.
  • Asylia Therapeutics
  • Atom Mines
  • Baylor College of Medicine
  • Baylor University
  • InformAI, Inc.
  • Iterion Therapeutics, Inc.
  • PanTher Therapeutics, Inc
  • PLUS Therapeutics, Inc.
  • Rapamycin Holdings, Inc.
  • Rice University
  • Stellanova Therapeutics, Inc.
  • Texas A&M Engineering Experiment Station
  • Texas A&M University
  • Texas A&M University System
    Health Science Center
  • Texas Health Institute
  • Texas Tech University Health Sciences Center
  • The Methodist Hospital Research Institute
  • The Rose
  • The University of Texas at Arlington
  • The University of Texas at Austin
  • The University of Texas at Dallas
  • The University of Texas Health Science Center at Houston
  • The University of Texas Health Science Center at San Antonio
  • The University of Texas Health Science Center at Tyler
  • The University of Texas M.D. Anderson Cancer Center
  • The University of Texas Medical Branch at Galveston
  • The University of Texas Southwestern Medical Center
  • University Health System
  • University of Houston
  • University of Houston - Downtown
  • Xerient Pharma, Inc.

Research Findings and Grantee Highlights in 2022

CPRIT’s $3.12 billion investment in 1,794 of the best ideas in cancer research, product development, and prevention enhances Texas’ role in the global fight against cancer. A snapshot of some notable research findings reported in fiscal year 2022, as well as other important milestones, awards and prestigious appointments, and prevention outreach, are shown below. Click on "View or Download All" to see all the information reported for the fiscal year.

Published Research Findings
View or Download All
Product Development Milestones
View or Download All
Awards and Prestigious Appointments
View or Download All
Prevention Outreach
View or Download All